Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine
Tóm tắt
This study aims to prepare candidate vaccines for cervical cancer immunotherapy by inserting the fused genes of human papillomavirus (HPV)16/18/58 mE6E7 lacking transforming activity into an adenovirus vector and to verify its efficiency in model mice with tumor expressing the associated HPV genes. The E6/E7 genes of HPV16/18/58 were point-mutated to abolish their transforming activity, and adenovirus (AD)-HPV16/18/58 mE6E7 adenovirus vaccine was constructed. The immune effect of the adenovirus vaccine against HPV16/18/58-type tumors was analyzed by tumor morphology, enzyme linked immunosorbent assay, enzyme-linked immunospot and specific cytotoxic T lymphocyte (CTL) and T lymphocyte subsets. The HPV16/18/58 mE6E7 plasmid containing point mutations was verified by quantitative real-time polymerase chain reaction (qRT-PCR), enzyme digestion and electrophoresis, and gene sequencing. qRT-PCR and Western blots verified that AD-HPV16/18/58 mE6E7 could express the HPV16 mE6E7, HPV18 mE6E7 and HPV58 mE6E7 fusion genes and proteins in cells. The results of animal experiments were as follows: In the vaccine group, the tumors formed later, the incubation period was longer, the growth was slower, growth was inhibited, and the survival period was significantly prolonged. The immunological results all showed that the vaccine could induce effective humoral and cellular immunity in mice with three types of tumors, compared with the phosphate buffered saline (PBS) group and the adenovirus-negative control (AD-NC) group, the differences were statistically significant (P < 0.05). We successfully constructed the HPV16/18/58 trivalent therapeutic adenovirus vaccine AD-HPV16/18/58 mE6E7. The AD-HPV16/18/58 mE6E7 adenovirus vaccine can protect immunized mice to a certain extent from TC-1, U14/LV-HPV18 E6E7 and U14/LV-HPV58 E6E7 cells, which contain HPV16, 18 and 58 E6 and/or E7 genes, respectively.
Tài liệu tham khảo
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
Feng YC, Wang SY, Zhang Y, et al. Genome-wide profiling of human papillomavirus DNA integration into human genome and its influence on PD-L1 expression in Chinese Uygur cervical cancer women. J Immunol Res. 2020;2020:1–12.
Zur HH. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–50.
Wen N, Meng YG. The pathogenic mechanism and research progress of HPVE6/E7 a in cervical cancer. Chin J Clin Obstet Gynecol. 2017;18(1):92–4.
Giorgi Rossi P, Chini F, Bisanzi S, et al. Distribution of high and low risk HPV types by cytological status: a population based study from Italy. Infect Agent Cancer. 2011;6:2.
Bao YP, Li N, Wang H. Study on the distribution of human papillomavirus types in cervix among Chinese women: a meta-analysis. Chin J Epidemiol. 2007;28(10):941–6.
Xie XX. The study of human papillomavirus virus-like particle based prophylactic vaccine. PeKing Union Medical College, 2013.
Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078–88.
Youn JW, Hur SY, Woo JW, et al. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncol. 2020;21(12):1653–60.
Wang H, Yu JY, Li L. Preliminary observation on antitumor effect of HPV58 composite DNA vaccine. Zhonghua Fu Chan Ke Za Zhi. 2013;48(7):523–7.
Lin KY, Guarnieri FG, Staveley O’Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Can Res. 1996;56(1):21–6.
Xie Q, Zhou ZX, Li ZL, et al. Transforming activity of a novel mutant of HPV16 E6E7 fusion gene. Virol Sin. 2011;26(3):206–13.
Li A, Zheng J, Lai BC, et al. Construction of a recombinant expression vector of human papillomavirus type 18 L1–E6, L1–E7 and expression of the chimeric gene in CHO cells. Chin J Cell Mol Immunol. 2002;18(6):558–61.
Wang H, Yu JY, Li L. Construction and identification of PVAX1-HPV58mE6E7fc-hIL12 composite DNA vaccine vector. Chin J Immunol. 2012;28(12):1110–4.
Ma WH. Construction of HPV16/18/58 trivalent therapeutic adenovirus vector vaccine and its anti-hpv58 tumor immune effect. Guangxi Medical University, 2017.
Xu YS. Experimental study on identification and modification of HLA-A2-restricted cytotoxic t lymphocyte epitopes derived from E7 antigen of HPV16. Third Military Medical University; 2003.
Zhang Q, Zheng FY, Xu YS, et al. Preliminary screening of HLA-A2-restricted CTL epitope derived from human papillomavirus 18E7 antigen. J Wenzhou Med Univ. 2007;37(02):100–3.
Chen LL. Prediction and immune responsibility identification of HLA restrictive epitopes derived from HPV58E6. Guangxi Medical University; 2016.
Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131(10):2349–59.
Zhang J, Gao B, Kang Y, et al. Genotype distribution of human papillomavirus strains in cervix samples from Chinese women: a meta-analysis. Chin J Microbiol Immunol. 2014;34(12):913–20.
Vici P, Pizzuti L, Mariani L, et al. Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Rev Vaccines. 2016;15(10):1327–36.
Li J, Liu BY, Zur Hausen H, et al. Investigation of human papillomavirus (HPV) infection in cervical carcinoma tissues of Chinese women. Chin J Exp Clin Virol. 1996;10(1):50–5.
Liu BY, Li J, De Villiers EM, et al. Investigation on relationship between the papillomavirus type 58 (HPV58) infection and cervix cancer in China. Chin J Exp Clin Virol. 1996;10(2):118–21.
Herrero R. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis. 2009;199(7):919–22.
Nominé Y, Masson M, Charbonnier S, et al. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell. 2006;21(5):665–78.
Lu Y, Zhang Z, Liu Q, et al. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model. Biol Pharm Bull. 2007;30(1):150–6.
Li LL, Wang HR, Zhou ZY, et al. C3-Luc cells are an excellent model for evaluation of cellular immunity following HPV16L1 vaccination. PLoS ONE. 2016;11(2):1–15.
Nakagawa S, Watanabe S, Yoshikawa H, et al. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. Virology. 1995;212(2):535–42.
Demers GW, Espling E, Harry JB, et al. Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J Virol. 1996;70(10):6862–9.
Zhao L, Ren J, Feng J, et al. Construction of recombinant vaccinia virus expressing HPV18E7E6 fusion proteins and detection of its immunogenicity in mice. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2008;22(3):189–91.
Wang H, Yu JY, Li L. Transformation activity and antigenicity of the human papillomavirus type 58 E6E7 fusion gene mutant. Chin J Oncol. 2013;35(7):491–6.
Wang H, Yu J, Li L. A DNA vaccine encoding mutated HPV58 mE6E7-Fc-GPI fusion antigen and GM-CSF and B7.1. Onco Targets Ther. 2015;8:3067–77.
Jia YY, Tan WJ, Duan FF, et al. A genetically modified attenuated listeria vaccine expressing HPV16 E7 kill tumor cells in direct and antigen-specific manner. Front Cell Infect Microbiol. 2017;7:1–11.
Zeng XC, Zhou GM, Li H, et al. Advances in studies on toxicity of gene therapy drugs mediated by adenovirus vectors and their mechanism. Drug Eval Res. 2012;35(1):27–30.
Venuti A, Massa S, Mett V, et al. An E7-based therapeutic vaccine protects mice against HPV16 associated cancer. Vaccine. 2009;27(25–26):3395–7.
Wang H, Yu JY, Li L. Construction and eukaryotic expression of PVAX1-HPV58mE6E7FcGB composite gene vaccine. J Biomed Eng. 2013;30(5):1102–7.
Zhao L. Construction and immunogenic study of polyvalent recombinant vaccinia virus vaccine for HPV16, HPV18 and HPV58. Chinese Center for Disease Control and Prevention; 2008.
Wick DA, Webb JR. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors. Vaccine. 2011;29(44):7857–66.
Gao M, Gao LM, Wu J, et al. Screening of ginsenoside adjuvant with therapeutic human papillomavirus-16 recombinant vaccine. Chin J Mod Appl Pharm. 2019;36(4):406–10.
Zhang Y, Tang J. HSP110 as an adjuvant on the nanoparticle vaccine of cervical cancer can effectively prolong the survival rate of tumor-bearing mice. Immunol J. 2018;34(4):277–85.
Huang B, Mao CP, Peng S, et al. RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency. Hum Gene Ther. 2008;19(8):763–73.